Side-by-side · Research reference

HGH 191AAvsPT-141

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED0/75 cited

BFDA-ApprovedHUMAN-REVIEWED13/41 cited

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

PT-141

MC4R Agonist · FDA-Approved (HSDD)

1.75 mgPer doseVYLEESI (bremelanotide injecti 2019

Pre-sexTimingVYLEESI (bremelanotide injecti 2019

~2.7 hrHalf-lifeVYLEESI (bremelanotide injecti 2019

SQ · Abdomen / thigh · ≥45 min before sex

01Mechanism of Action

Parameter

HGH 191AA

PT-141

Primary target

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023 VYLEESI (bremelanotide injecti 2019

Pathway

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023

Downstream effect

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015

Feedback intact?

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

—

Origin

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019

Antibody development

Rare — <2% develop binding antibodies, typically non-neutralizing

—

02Dosage Protocols

Parameter

HGH 191AA

PT-141

Pediatric GHD

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

—

Adult GHD

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

—

Turner syndrome

0.045–0.050 mg/kg/day SQ

—

Idiopathic short stature

0.037 mg/kg/day SQ

—

AIDS wasting

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

—

Frequency

Once daily, typically evening

Evening administration mimics physiological GH pulse.

PRN, max 8 doses / month

Evidence basis

FDA-approved / decades of RCT data

FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019 Clayton 2015

Monitoring

IGF-1, glucose, thyroid function, bone age (children)

—

Duration

Years (children until epiphyseal closure); indefinite (adult GHD)

PRN; reassess if no benefit after 8 doses

Standard dose

—

1.75 mg SQVYLEESI (bremelanotide injecti 2019

Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.

Lower / starter dose

—

1 mg (off-label)

Reconstitution

—

Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.

Timing

—

≥45 min before sexual activity

Half-life

—

~2.7 hrVYLEESI (bremelanotide injecti 2019

03Metabolic / Fat Loss Evidence

Parameter

HGH 191AA

PT-141

Primary fat target

Visceral and subcutaneous adipose tissue

—

Mechanism

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

—

Effect on lean mass

Significant lean mass increase (protein synthesis, nitrogen retention)

—

Insulin sensitivity

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

—

IGF-1 elevation

Dose-dependent, significant — primary anabolic mediator

—

Glucose metabolism

Hyperglycemia risk, especially high doses (AIDS wasting)

—

Body composition

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

—

Clinical context

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

—

04Side Effects & Safety

Parameter

HGH 191AA

PT-141

Injection site reaction

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

Erythema, mild pain

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

—

Glucose intolerance

Hyperglycemia, new-onset diabetes (anti-insulin effect)

—

Intracranial hypertension

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

—

Slipped capital femoral epiphysis

SCFE risk in children — limp, hip/knee pain (requires surgery)

—

Scoliosis progression

Rapid growth may unmask/progress scoliosis (monitor spine in children)

—

Hypothyroidism

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

—

Cancer risk

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

—

Antibody formation

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

—

Pancreatitis

Rare. Higher risk in children with certain syndromes (Prader-Willi).

—

Gynecomastia

Adolescent males (physiological during puberty, may be exacerbated)

—

Nausea

—

Common (~40%); often transientVYLEESI (bremelanotide injecti 2019

Flushing

—

Common, transient

Headache

—

Common

Hyperpigmentation (focal)

—

Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019

Hypertension (transient)

—

Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019

Pregnancy / OB

—

Contraindicated

Cardiovascular disease

—

Use caution; transient BP rise

Absolute Contraindications

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

PT-141

·Uncontrolled hypertension
·Known cardiovascular disease (caution)
·Pregnancy

Relative Contraindications

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

PT-141

·Pre-existing hyperpigmentation disorders
·MC4R-pathway-dependent psychiatric conditions

05Administration Protocol

Parameter

HGH 191AA

PT-141

1. Reconstitution (if lyophilized)

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.

2. Injection site

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

SQ — abdomen or thigh.

3. Timing

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.

4. Storage

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.

5. Needle

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.

6. Monitoring

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

—

06Stack Synergy

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms

PT-141

— no documented stacks